EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2

Manya Bakatumana Hans iD, Anita Moendat Fanto iD, Tsutomu Fukuda iD, Koushirou Suga, Masatomo Iwao, Hideki Hayashi iD, Masaru Yokoyama iD, Hironori Sato iD, Olivier Tshiani Mbaya iD, Osamu Kotani, Yoshinao Kubo iD

International Journal of Molecular Sciences · 09.03.2026 · 27 (5) · 2501

DOI: 10.3390/ijms27052501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.03.2026. Verfasst von Manya Bakatumana Hans und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan. Hauptthemen laut MEDLINE: Lassa virus, Genetic Vectors, Virus Replication, Drug Resistance, Viral. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, WISE grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A high-risk infectious disease or a Category A pathogen, Lassa virus (LASV), requires strict containment, classified as biosafety level 4 (BSL-4) conditions, which restricts research on the virus due to the scarcity of BSL-4 facilities. Thus, replication-defective pseudotyped retroviral vectors have been widely used as safe materials for neutralizing activity assays of drugs and antibodies in BSL-2. Here, we established a novel retroviral vector system encoding LASV glycoprotein complex (GPC) that can exclusively replicate in cells expressing the Gag-Pol protein of murine leukemia virus (MLV) under BSL-2 conditions. Using this conditional replication system, we successfully isolated LASV GPC variants resistant to either an anti-LASV compound, lamellarin α 20-sulfate, or a neutralizing antibody derived from a Lassa fever survivor. In the lamellarin α 20-sulfate-resistant variants, K125E and H13R amino acid substitutions cooperatively conferred resistance. The K125E enhanced infectivity and simultaneously conferred a lethal effect on cells in the conditional replication system, while the H13R mitigated the latter effect, thereby enabling stable expression of LASV GPC in cells. In the neutralizing antibody-resistant variants, I403T substitution was responsible for the resistance by impairing antibody binding. This study provides a valuable BSL-2-based platform for isolating LASV GPC variants resistant to inhibitors and characterizing their mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lassa virusGenetic VectorsVirus ReplicationDrug Resistance, ViralGlycoproteinsRetroviridaeViral Envelope ProteinsAnimalsHumansCell LineMiceAntiviral AgentsAntibodies, NeutralizingLassa Fever

Stichwörter der Autor:innen

Lassa virusglycoproteinmurine leukemia virusretroviral vector

Substanzen

GlycoproteinsViral Envelope ProteinsAntiviral AgentsAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.
  • Institut National de Recherche Biomedicale, Kinshasa P.O. Box 1197, Democratic Republic of the Congo.
  • Program for Nurturing Global Leaders in Tropical Medicine and Emerging Communicable Diseases, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
  • Environmental Protection Center, Nagasaki University, Nagasaki 852-8523, Japan.
  • Graduate School of Integrated Science and Technology, Nagasaki University, Nagasaki 852-8523, Japan.
  • Organization for Marine Science and Technology, Nagasaki University, Nagasaki 852-8523, Japan.

ORCID-Profile: Manya Bakatumana Hans, Anita Moendat Fanto, Tsutomu Fukuda, Hideki Hayashi, Masaru Yokoyama, Hironori Sato, Olivier Tshiani Mbaya, Yoshinao Kubo

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • WISE grant
  • Asahi Kasei Life Science Co. LTD
  • AMED
  • WISE

Zitieren

APA

Hans, M. B., Fanto, A. M., Fukuda, T., Suga, K., Iwao, M., Hayashi, H., Yokoyama, M., Sato, H., Mbaya, O. T., Kotani, O., & Kubo, Y. (2026). Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2. International Journal of Molecular Sciences, 27(5), 2501. https://doi.org/10.3390/ijms27052501

Vancouver

Hans MB, Fanto AM, Fukuda T, Suga K, Iwao M, Hayashi H, et al. Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2. International Journal of Molecular Sciences. 2026;27(5):2501. doi:10.3390/ijms27052501

BibTeX
@article{Hans2026,
  author = {Hans, Manya Bakatumana and Fanto, Anita Moendat and Fukuda, Tsutomu and Suga, Koushirou and Iwao, Masatomo and Hayashi, Hideki and Yokoyama, Masaru and Sato, Hironori and Mbaya, Olivier Tshiani and Kotani, Osamu and Kubo, Yoshinao},
  title = {Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {2501},
  doi = {10.3390/ijms27052501}
}
Kostenlos starten →